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Abstract Physicians are increasingly aware that asthma causes significant impairmentofthe patient’s physical, psycho-
logical, and social well-being.Whilst standard clinical endpoints provide significant information on airway status during
treatment, it is importantto determinewhether such improvements overcome the functional impairmentthat patients
have to deal with on a daily basis. As such, assessment of health-related quality of life (QoL) is an important aspect of
asthma management in clinical practice.Omalizumab (Xolairs) is a recombinant humanizedmonoclonal anti-immuno-
globulin E (IgE) antibody that represents a new therapeutic approachto IgE-mediated diseases such as allergic asthma.
Clinical studies show thatomalizumab improves the control of allergic asthmawhilst reducing steroid consumption, and
enhanceslong-termdisease controlinpatientswithrecurrent symptoms.UsingestablishedandvalidatedQoLmethodol-
ogy, two placebo-controlled clinical studies in adultswithmoderate-to-severe allergic asthma have shownthat patients
treated with omalizumab experience a clinically relevant improvement in all aspects of their asthma-related QoL,
changes that were significantly superior to those observed for placebo. Such improvementswere apparent when oma-
lizumabwas added to existing therapy with inhaled corticosteroids, andmaintained duringa subsequent steroid-reduc-
tionphase.Through effective disease control, omalizumab therefore leads to significant improvements in health-related
QoL that aremeaningful to patientswith allergic asthma. r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Asthma continues to represent a major public health
concern, a¡ecting some 100^150 million people world-
wide and accounting for an estimated180 000 deaths on
an annual basis (1).Highest prevalence rates are apparent
in developed countries (2), where asthma consumes a
considerable proportion of scarce health-care resources
(3). Current international and national asthma manage-
ment guidelines advocate the importance of combined
pharmacotherapy to control the underlying in£amma-
tory disease (e.g. inhaled corticosteroids) and relieve
acute symptoms (e.g. short-acting inhaled b2-agonists)
(4^6). However, such regimens can be complicated (e.g.
use of multiple inhalers with di¡erent administration
schedules) and are often, therefore, associated with
poor patient compliance, which represents a major ob-
stacle to successful disease control in the long term. A
need therefore exists for new therapeutic options forReceived 26 August 2002
Correspondence should be addressed to: Prof.Roland Buhl, Pulmonary
Department,University Hospital,Mainz,Germany.Tel: +49 6131177270;
Fax: +49 6131175545; E-mail: r.buhl@3-med.klinik.uni-mainz.dethe treatment of asthma that are e¡ective, well toler-
ated and above all convenient for the patient.
Recent evidence con¢rms that over 90% of asthma
cases are allergic in nature (7,8).Trigger allergens include
housedust mites, pollens, animal danders and fungal
spores. Targeting of factors involved in the subsequent
allergen-speci¢c response, such as immunoglobulin E
(IgE) (9), therefore represents a sound basis for the de-
velopment of new therapeutic agents for the treatment
of asthma.Moreover, many asthma su¡erers have other
concomitant IgE-mediated allergic diseases such as sea-
sonal allergic rhinitis (2), which means that a treatment
aimed at stopping the e¡ects of IgE in the allergic cas-
cade may bring about improvements in both conditions.
This scienti¢c rationale has led to the development of
omalizumab (Xolairs), the ¢rst agent to speci¢cally tar-
get human IgE.Omalizumab is a recombinant humanized
monoclonal anti-IgE antibody that stops the allergic
cascade by binding to free IgE (10). Indeed, studies show
that serum-free IgE levels fall to approximately 1% of
baseline values within 24h of subcutaneous administra-
tion of omalizumab, an e¡ect that is maintained with
continued administration (11^13). Consequently, IgE re-
ceptors on cells involved in the allergic response are
124 RESPIRATORYMEDICINEdown-regulated, leading to a decreased responsiveness
to antigen challenge (14).This pro¢le of reduced free IgE
levels and IgE receptor down-regulation suggests that
omalizumab is a promising new agent for the treatment
of allergic asthma and other allergic diseases. Indeed,
early initial studies in patients with mild allergic asthma
showed that omalizumab signi¢cantly inhibited the early
and late responses to inhaled allergen (15), which pro-
vides evidence that IgE has a central role in mediating
the allergic cascade. Given that the late asthmatic re-
sponse is generally regarded to re£ect the chronic in-
£ammatory changes characteristic of the disease (16),
the inhibitory e¡ects of omalizumab demonstrate its po-
tential utility in the long-term management of asthma.
Indeed, two long-term (28-week) clinical studies have
subsequently con¢rmed that omalizumab is e¡ective in
the treatmentof adultswithmoderate-to-severe allergic
asthma (17,18).This e¡ectwasmaintained during a subse-
quent 24-week extension period (19). In these studies,
omalizumab was well tolerated and signi¢cantly im-
proved both standard clinical endpoints and overall dis-
ease control [i.e. the number of asthma exacerbations
per patient was reduced (Fig.1)], and provided patients
with the opportunity to signi¢cantly lessen their depen-
dence on inhaled corticosteroids. With any new treat-
ment intervention for asthma, however, the question
always remains as to whether statistically signi¢cant im-
provements in symptoms and disease control are clini-
cally relevant from the patients’ perspective, notably in
terms of their health-relatedqualityof life (QoL).For this
reason, an assessment of the e¡ect of omalizumab on
health-related QoL formed an integral part of this com-
pound’s clinical development.
This review discusses the e¡ects of asthma on health-
relatedQoL andhow it canbe quanti¢ed, along with the
pooled ¢ndings of clinical investigations of the e¡ect ofOmalizumab
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FIG. 1. Meannumberof asthmaexacerbationsperpatientdur-
ing treatment with omalizumab in adult and adolescent patients
with moderate-to-severe asthma, when added to existing in-
haled corticosteroid therapy (steroid-stable phase; 16 weeks)
andwhen inhaled corticosteroidswere reduced (steroid-reduc-
tion phase; 12 weeks); **Po0.01, ***Po0.001vs. placebo (using
the generalized Cochran^Mantel^Haenszel test).omalizumab on health-related QoL in adults and adoles-
cents with allergic asthma.
THEEFFECTOFASTHMAON
HEALTH-RELATEDQOL
Aprimaryobjective ofmedicalpractice is to improve the
patient’s health-relatedQoL, i.e. the aspects of an indivi-
dual’s overall QoL that is principally determined by his/
her health status andwhich is sensitive to therapeutic in-
tervention. Health-related QoL can therefore be simply
and adequatelyde¢ned as ‘the functional aspects of an ill-
ness and its consequent therapy upon a patient, as per-
ceived by the patient’ (20), a de¢nition that places
emphasis on health and associated impairments that pa-
tients consider important.Use of such a focused de¢ni-
tion is important, as the expression ‘quality of life’ is
somewhat nebulous and often means di¡erent things to
di¡erent individuals.
It is well established that asthma exerts a profound ef-
fect on QoL, particularly from an emotional aspect and
in terms of the ability to perform activities (21). Indeed, it
is often the extent of such functional impairment, and
the inability to perform day-to-day activities as well or
as enjoyably as the su¡erer would like, that leads to the
primary medical consultation rather than actual symp-
toms of shortness of breath, wheezing and cough per se.
For example, patients typicallyexperience di⁄culty with
sports and exercise, while day-to-day tasks such as going
upstairs and shoppingmaybe troublesome due to short-
ness of breath. Environmental stimuli, such as exposure
to allergens (e.g. dust, pets), cigarette smoke, cold air
and atmospheric pollution, may also cause di⁄culties
with daily activity. Such limitations are a cause of signi¢-
cant frustration to patients.Other emotional aspects in-
clude concerns about having asthma, particularly the
need to use medications in the long-term and fear of
not havingmedication available should a life-threatening
episode occur (22).Until recently, however, clinical trials
in patients with asthma have tended to focus on conven-
tional clinical indices of the illness alone (e.g. spirometry,
symptoms, airwayshyperresponsiveness).This canpartly
be explained by the tremendous medical advances that
have occurred over the last three decades in the diagno-
sis of the disease and evaluation of treatment interven-
tion. Such advances have caused a shift away from
reliance on traditional medical history taking, which
usually included an assessment of symptoms as well as
how the patient’s daily life was a¡ected and the asso-
ciated impact on his/her feelings. Moreover, evaluation
of the subjective experiences of the patient has often
been overlooked on the basis that such experiences
are merely qualitative and often vague. Studies designed
around an evaluation of clinical outcomes alone have,
therefore, often assumed thatchanges in theseendpoints
OMALIZUMABANDQUALITYOFLIFE 125would lead to concomitant changes in the patient’s daily
life, thereby conferring a QoL improvement. However,
there is an increasing body of evidence to show that con-
ventional clinical measures of asthma, whilst providing
valuable information about the status of the a¡ected or-
gan system, rarely capture in full the functional impair-
ments that are important to patients in their everyday
lives (23). Conversely, some patients may experience an
improvement in health status during therapeutic inter-
vention but this improvement may not be captured by
clinical measures (24). To obtain a complete picture of
the patient’s health status during asthma therapy, there-
fore, both conventional clinical indices and the patient’s
health-related QoL, should be concomitantly measured
(25). Indeed, advances in QoL research, with the devel-
opment of rigorous scienti¢c questionnaires, now mean
that changes in subjective functional status can be reli-
ably and accurately determined during asthma therapy.
In conjunction with routine clinical measures of airways
function, such questionnaires help to provide a more
complete assessment of overall health status in the pa-
tient with asthma, and are discussed in more detail in
the following section.
MEASURINGHEALTH-RELATEDQOL
INPATIENTSWITHASTHMA
Arange of questionnaires, both generic and disease-spe-
ci¢c, are available to determinehealth-relatedQoL inpa-
tients with asthma (24).Generic instruments include the
Sickness Impact Pro¢le (26), the Nottingham Health
Pro¢le (27), and the Medical Outcomes Survey Short-
Form 36 questionnaire (28). These questionnaires are
designed for use in all health states, and therefore allow
burden of illness to be compared for di¡erent medical
conditions. To do so, however, requires that such ques-
tionnaires are broad in their comprehensiveness; conse-
quently, they have little scope to detect small, but
subjectively important, changes in health-related QoL
for patients with speci¢c conditions such as asthma (29).
The limitations of generic instruments have led to the
developmentof disease-speci¢cQoL questionnaires that
aim to determine the level of impairment patients with a
speci¢c disease experience during their daily life. Such
questionnaireshavebeen developed andvalidated for pa-
tients with asthma, and can be used in both clinical trials
and clinical practice to assess the impact of the condi-
tion, and subsequent treatment, on a patient’s QoL.
Examples of asthma-speci¢c QoL instruments are nu-
merous and include, amongst others, the Asthma Qual-
ity of Life Questionnaire (AQLQ) (22), the St George’s
Respiratory Questionnaire (30), the Living with Asthma
Questionnaire (31), and the Respiratory IllnessQuality of
Life Questionnaire (32). Of these instruments, the
AQLQ has been extensively utilized in clinical trials.Thisquestionnaire comprises 32 questions (frequently re-
ferred to as ‘items’), which were chosen by asking adult
patients with asthma to identify the aspects of their dis-
ease thatweremost troublesome to daily life.Questions
are grouped into four categories (‘domains’):
K Activity limitations: Amount of limitation of individual
activities that are important to the patient and are
a¡ected by asthma (11items).
K Emotions: Frequency of being afraid of not having
medications, concerns about having asthma and using
medication, and frustration (¢ve items).
K Symptoms: Frequency and discomfort associated
with shortness of breath, chest tightness, cough,
di⁄culty breathing out, ¢ghting for air, heavy
breathing, and di⁄culty getting a good night’s sleep
(12 items).
K Exposure to environmental stimuli: Frequency of
exposure to and avoidance of environmental stimuli
such as dust, cigarette smoke and air pollution (four
items).
Each question is answered by the patient on a 7-point
scale, from1 (extremely impaired) to 7 (no impairment).
Results are generally expressed in terms of a mean score
for each domain, alongwith an overall score. An increase
in domain or overallQoL score of 0.5 orgreater indicates
a clinically signi¢cant improvement in QoL, with di¡er-
ences from baseline greater than 1.5 re£ecting a ‘large’
improvement (33). This approach allows physicians to
make a meaningful interpretation of QoL ¢ndings, i.e.
to translate these thresholds into scenarios that illus-
trate what a clinically signi¢cant change with treatment
maymean to an individual patient (34). Independent vali-
dation studies show that AQLQ has good reliability and
responsiveness with excellent cross-sectional and longi-
tudinal validity (35), properties that make this question-
naire ideal for use in clinical trials (36).Moreover, AQLQ
has been adapted for use in a large number of languages
and can be completed by patients in 5^10min, making
this an idealmethod for assessment of the health-related
QoL of the asthma patient in routine clinical practice.
EFFECTOFOMALIZUMABON
HEALTH-RELATEDQOL
As previously discussed, omalizumab is a recombinant
humanized monoclonal anti-IgE antibody that has de-
monstrated signi¢cant clinical bene¢ts in adults with
moderate-to-severe allergic asthma in two phase III stu-
dies (17,18).These studiesutilized an identical double-blind,
placebo-controlled design, in which1071adolescents and
adults aged12^75 yearswithmoderate-to-severe allergic
asthma (baseline forcedexpiratory volume in1sec40%
and 80% of predicted), who were symptomatic on
inhaled corticosteroids, were enrolled. All patients had
126 RESPIRATORYMEDICINEexperienced asthma symptoms for at least 1 year, with
serum IgE levels of 30^700 IU/ml, and demonstrated po-
sitive skin-prick testing to at least one common allergen
(e.g. housedustmite, dog, cat or cockroach). Following a
run-in/baseline period, patients were randomized to re-
ceive either omalizumab or matching placebo for 16
weeks, in addition to existing treatment with inhaled
corticosteroids (steroid-stable phase). During the fol-
lowing12 weeks, controlled attempts weremade to gra-
dually reduce or withdraw corticosteroid therapy
(steroid-reduction phase). Health-related QoL, in addi-
tion to routine clinical endpoints, was assessed through-
outeach 28-week studyusing theAQLQ.Inboth studies,
omalizumab was administered as a subcutaneous injec-
tion once or twice each month (at least 0.016mg/kg/IgE
[IU/ml] every 4 weeks). Most patients, however, were
conveniently dosed atmonthly intervals.
The homogeneity of the design of the two studies
permitted pooling of their QoL ¢ndings. Overall, pa-
tients treated with omalizumab experienced a clinically
relevant improvement in their asthma-related QoL, as
shownby improvements inmean score of0.5 in all four
domains (as well as the overall score) of the AQLQ
(Fig. 2). It is interesting to note that therewere large re-
sponses in some patients on placebo, consistent with
previous observations (37^41), although a signi¢cant pla-
cebo response is not unique to patients with asthmaSymptomEmotionsActivities
M
ea
n 
ch
an
ge
 fr
o
m
 b
as
el
in
e
1.5
1.0
0.5
0
*** ***
***
SymptomEmotionsActivities
M
ea
n 
ch
an
ge
 fr
o
m
 b
as
el
in
e
1.5
1.0
0.5
0
*** ***
***
Omalizuma
Placebo
(a)
(b) Domain
End of steroid-sta
End of steroid-red
FIG. 2. Pooledanalysisof least-squaresmeanimprovementsin ast
III studiesof adult andadolescentpatientswithmoderate-to-severe
ods).(42^45). Such responses, especially in the clinical trial
setting, are often attributed to psychological mechan-
isms such as an awareness of being closely observed and
active compliancewith thepresumedwishes of research-
ers, along with improved compliancewith existingmedi-
cation.Nevertheless, these placebo responses were still
signi¢cantly lower than the improvements in QoL
achieved with omalizumab (Fig. 2), and improvements
for the latter group were consistent with other e⁄cacy
evaluations. Overall, the level of improvement in QoL
with omalizumab during the steroid-stable phase was
higher than that observedwith either leukotriene-mod-
ifying agents (41) or low-dose inhaled corticosteroids
alone (46), and comparable to that observed for salme-
terol when added to the regimen of a similar population
ofpatients symptomatic on inhaledcorticosteroids alone
(37,39).
Aparticularlynotable ¢ndingof these studieswas that
the improvement in QoL with omalizumab was main-
tainedwhen controlled attemptsweremade togradually
taper the dose of inhaled corticosteroid; in fact, the po-
sitive e¡ect of omalizumab therapy on QoL relative to
placebo appeared to increase as patients progressed
through this stage of the study (see Fig. 2).Themagnitude
of this improvement is particularly apparent if we exam-
ine the proportion of patients experiencing a ‘large’ im-
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FIG. 3. Pooledanalysisofpercentageofpatients achievinga‘large’improvementinasthma-relatedQoL (increaseindomainoroverall
score of1.5 ormorerelativetobaseline (33)) during treatmentwithomalizumabintwophase III studiesof adult andadolescentpatients
with moderate-to-severe asthma; *Po0.05, **Pr0.01, ***Pr0.001 vs. placebo (using the generalized Cochran^Mantel^Haenszel
test).
OMALIZUMABANDQUALITYOFLIFE 127and/or overall QoL score increased from baseline by 1.5
points ormore (33). Indeed, comparedwith placebo, the
proportion of patients achieving this level of QoL im-
provement on omalizumab was signi¢cantly higher
across all aspects of asthma-related QoL (Fig. 3). Thus,
in terms of overall score, 31% of omalizumab-treated pa-
tients achieved a large improvement inQoL, almost two-
foldhigher than that observed for placebo (18%).This im-
provement is notable when we consider that it was
achieved despite a signi¢cant concomitant reduction in
reliance on inhaled corticosteroids. Such ¢ndings there-
fore provide compelling evidence that omalizumab tar-
gets a cause of the underlying allergic disease.
Overall, the QoL bene¢ts conferred by omalizumab
therapy are con¢rmed by patient and investigator
opinions of treatment e¡ectiveness, which were re-
corded at the end of the 28-week treatment period in
both phase III studies. Indeed, over 60% of patients and
investigators rated treatmentwith omalizumab as either
‘excellent’or ‘good’, comparedwith less than 40% for pla-
cebo therapy. Consequently, the proportion of patients
and investigators rating omalizumab therapy as ‘poor’(or ‘worse’ relative to pre-treatment) was low (only
14%), whereas 33% of patients and investigators re-
corded such an evaluation for placebo therapy. Overall,
omalizumab was signi¢cantly superior to placebo in
terms of patient and investigator opinions of treatment
e¡ectiveness (both Po0.001).
CONCLUSIONS
It is well established that asthma can have an adverse ef-
fect on the physical, emotional, and social aspects of an
individual’s QoL. Paradoxically, clinical trials in patients
with asthma have tended to focus on standard evalua-
tions of airway status alone, with little regard as to
whether such changes are clinically meaningful from the
patient’s perspective. Indeed, improvements in health-
relatedQoLhave oftenbeen assumedon thebasis of sta-
tistically signi¢cant changes in clinical endpoints. How-
ever, such correlation is typically weak to moderate,
which emphasizes the importance of a concomitant eva-
luation of health-related QoL during clinical assessment.
128 RESPIRATORYMEDICINEWith the developmentof rigorous, disease-speci¢c ques-
tionnaires, such as the AQLQ, changes in subjective func-
tional status can now be reliably and accurately
determined, thereby provide a more complete assess-
ment of overall health status during asthma therapy.
Omalizumab is a new preventative therapy that targets
an important cause of allergic asthma, the IgE-mediated
allergic response. In clinical studies, this agent provided
e¡ective disease control in adults with moderate-to-se-
vere allergic asthma, a pro¢le that was paralleled by sig-
ni¢cant improvements in all aspects of asthma-related
QoL. Such improvements were clinically meaningful to
patients, and were evident not only when omalizumab
was added to existing therapy with inhaled corticoster-
oids but also during a subsequent steroid-reduction
phase. Moreover, with convenient subcutaneous admin-
istration once or twice each month, treatment with
omalizumab may overcome the potential for poor com-
pliance that has proved a major limitation of traditional
anti-asthma agents.On the basis of such ¢ndings, omali-
zumab therefore represents a novel andhighly promising
addition to available pharmacotherapies for the treat-
ment of asthma.
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